Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta‐analysis

Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta‐analysis

Abstract Background By prolonging overall survival and reducing disease recurrence rates, immune checkpoint inhibitors (ICIs) are an emerging adjuvant therapy option for patients with resectable malignant tumors. However, the safety profile (deaths and adverse events [AEs]) of adjuvant ICIs has not...

Full description

Bibliographic Details
Main Authors: Ruiyang Xie, Jie Wu, Bingqing Shang, Xingang Bi, Chuanzhen Cao, Youyan Guan, Hongzhe Shi, Jianzhong Shou
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Cancer Innovation
Subjects:
immune checkpoint inhibitor
adjuvant therapy
cancer
adverse event
death
Online Access:https://doi.org/10.1002/cai2.34

Internet

https://doi.org/10.1002/cai2.34

Similar Items